Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek	⤷ Start Trial	68304	⤷ Start Trial
MP Biomedicals	⤷ Start Trial	190194	⤷ Start Trial
MolPort	⤷ Start Trial	MolPort-003-666-173	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 19, 2026

This report identifies and analyzes key bulk active pharmaceutical ingredient (API) sources for dyclonine hydrochloride. It details manufacturing capabilities, regulatory compliance, and historical supply trends to inform strategic sourcing decisions for pharmaceutical companies.

What is Dyclonine Hydrochloride?

Dyclonine hydrochloride is a topical anesthetic. It acts by blocking sodium ion channels in sensory neurons, preventing the initiation and conduction of nerve impulses. This mechanism of action makes it effective for temporary relief of pain and itching.

Chemical and Physical Properties

Chemical Name: 1-(4-ethoxy-3-phenylbutyl)piperidin-4-yl cyclohexanecarboxylate hydrochloride
CAS Number: 5560-77-0
Molecular Formula: C18H27NO2 · HCl
Molecular Weight: 325.87 g/mol
Appearance: White to off-white crystalline powder
Solubility: Soluble in water and ethanol

Pharmaceutical Applications

Dyclonine hydrochloride is primarily used in over-the-counter (OTC) and prescription topical formulations. Common applications include:

Sore throat sprays and lozenges
Anti-itch creams and ointments for minor skin irritations
Pre-operative topical anesthesia for minor procedures

Global API Manufacturing Landscape for Dyclonine Hydrochloride

The manufacturing of dyclonine hydrochloride API is concentrated in regions with established chemical synthesis infrastructure and pharmaceutical manufacturing capabilities. Key manufacturing hubs include China and India.

Major Manufacturing Regions and Countries

China: Holds a significant share of global dyclonine hydrochloride API production. Several Chinese chemical manufacturers specialize in API synthesis and export.
India: A substantial producer and exporter of APIs, including dyclonine hydrochloride. Indian manufacturers often benefit from a large skilled workforce and competitive pricing.
Europe and North America: Limited direct API manufacturing for dyclonine hydrochloride. Companies in these regions may source API from Asian manufacturers and perform final formulation and packaging.

Leading API Manufacturers

Identification of specific manufacturers requires access to proprietary market intelligence and supply chain databases. However, based on historical trade data and industry directories, key players are often found among companies with broad portfolios of topical anesthetics and fine chemicals. Companies that consistently appear in sourcing lists for similar APIs include:

Companies in China: Several large chemical synthesis enterprises based in provinces like Jiangsu, Zhejiang, and Shandong are known to produce a range of APIs. Specific company names are proprietary and subject to change based on production capacity and market focus.
Companies in India: Manufacturers located in Gujarat and Maharashtra are prominent in the Indian API sector. Again, specific company identifiers are dynamic.

Manufacturing Processes and Quality Standards

The synthesis of dyclonine hydrochloride involves multi-step organic chemical reactions. Key considerations for manufacturers include:

Good Manufacturing Practices (GMP): Adherence to international GMP standards (e.g., ICH Q7) is mandatory for APIs intended for pharmaceutical use. This ensures consistent quality, purity, and safety.
Impurity Profiling: Rigorous testing for process-related impurities, residual solvents, and degradation products is critical.
Analytical Testing: Comprehensive analytical methods, including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Mass Spectrometry (MS), are employed for quality control.

Regulatory Compliance and Market Access

Access to key pharmaceutical markets is contingent upon API manufacturers meeting stringent regulatory requirements.

Key Regulatory Bodies and Requirements

U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with FDA regulations, including GMP and facility inspections. Drug Master Files (DMFs) are often submitted to the FDA for review.
European Medicines Agency (EMA): For the European market, compliance with EMA guidelines and the European Pharmacopoeia (Ph. Eur.) is necessary. Certificates of Suitability (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) are often required.
Other National Regulatory Authorities: Manufacturers must also satisfy the requirements of regulatory bodies in other target markets (e.g., Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA)).

Importance of DMFs and CEPs

Drug Master Files (DMFs): These confidential documents submitted to regulatory agencies provide detailed information about the manufacturing, processing, packaging, and storage of the API. They allow regulatory bodies to review the API’s quality without disclosing proprietary information to the drug product applicant.
Certificates of Suitability (CEPs): Issued by the EDQM, a CEP confirms that an API complies with the relevant monograph in the European Pharmacopoeia. This simplifies the regulatory process for drug product manufacturers in Europe.

Supply Chain Dynamics and Risk Factors

The dyclonine hydrochloride API supply chain is subject to various dynamics and inherent risks.

Historical Supply and Pricing Trends

Price Volatility: API prices can fluctuate due to raw material costs, manufacturing capacity, global demand, and geopolitical factors. Historically, prices for many generic APIs have trended downwards due to increased competition, but raw material spikes can cause temporary upticks.
Capacity Utilization: Manufacturers’ capacity utilization rates directly impact supply availability and pricing. Periods of high demand or unexpected plant shutdowns can lead to shortages.
Geographic Concentration: The concentration of manufacturing in China and India presents a significant risk. Geopolitical tensions, trade disputes, or localized environmental regulations can disrupt supply.

Potential Supply Chain Disruptions

Raw Material Availability: Dependence on specific precursor chemicals can create vulnerabilities if their supply chains are disrupted.
Logistics and Transportation: Global shipping delays, port congestion, and increased freight costs can impact timely delivery.
Regulatory Changes: New or stricter environmental regulations in manufacturing countries can lead to plant closures or increased compliance costs, affecting supply and price.
Intellectual Property and Patent Expirations: While dyclonine hydrochloride is an established drug, understanding patent landscapes for novel delivery systems or improved synthesis routes is important for long-term supply security.

Strategies for Supply Chain Resilience

Dual Sourcing: Engaging with multiple qualified API manufacturers from different geographic regions mitigates single-source dependency.
Inventory Management: Maintaining adequate buffer stock of critical APIs can help weather short-term supply disruptions.
Supplier Audits and Qualification: Thorough due diligence, including regular audits of potential suppliers, is essential to ensure quality and compliance.
Contractual Agreements: Robust supply agreements with clear terms regarding quality, delivery timelines, and pricing are crucial.

Market Analysis and Future Outlook

The market for dyclonine hydrochloride API is primarily driven by the demand for OTC and prescription topical products.

Market Drivers

Increasing Prevalence of Skin Conditions: A growing aging population and increased awareness of skin health contribute to the demand for topical treatments.
Growth in OTC Pharmaceuticals: The expanding OTC market, particularly for symptomatic relief products, fuels demand for APIs like dyclonine hydrochloride.
Emerging Markets: Increased healthcare access and disposable income in emerging economies can drive demand for pharmaceutical products.

Market Challenges

Competition from Alternative Anesthetics: Other topical anesthetics, such as benzocaine, lidocaine, and pramoxine, compete directly with dyclonine hydrochloride.
Regulatory Scrutiny: Increasing regulatory oversight on API quality and manufacturing practices can raise compliance costs.
Generic Drug Pricing Pressures: Intense competition among generic API manufacturers often leads to downward pressure on prices.

Future Outlook

The market for dyclonine hydrochloride API is expected to remain stable, with moderate growth anticipated. Innovation in formulation technologies could potentially create new applications or enhance existing ones, thereby influencing API demand. Manufacturers focusing on high-quality GMP compliance, robust supply chains, and competitive pricing will be best positioned to serve this market.

Key Takeaways

Dyclonine hydrochloride API manufacturing is predominantly located in China and India, presenting potential supply chain risks due to geographic concentration.
Strict adherence to GMP standards and regulatory requirements (FDA, EMA) is critical for market access and product compliance.
Companies must implement strategies such as dual sourcing and robust inventory management to ensure supply chain resilience.
Market growth is supported by the increasing prevalence of topical treatment needs and the expanding OTC pharmaceutical sector.

Frequently Asked Questions

What are the primary regulatory hurdles for introducing a new dyclonine hydrochloride API supplier into the U.S. market? U.S. FDA approval hinges on the manufacturer's adherence to Current Good Manufacturing Practices (cGMP). This includes successful facility inspections, comprehensive documentation within a Drug Master File (DMF) for the API, and demonstrated control over the entire manufacturing process to ensure consistent quality and purity.
How can a pharmaceutical company best mitigate the risk of supply disruption from a single API manufacturer in China? A pharmaceutical company can mitigate single-source risk by establishing relationships with at least two qualified API manufacturers, preferably in different geographic regions (e.g., one in China and another in India). Implementing dual sourcing strategies, conducting regular supplier audits, and maintaining sufficient safety stock of the API are also critical measures.
What is the typical shelf life of dyclonine hydrochloride API, and what storage conditions are recommended? The typical shelf life of dyclonine hydrochloride API is generally two to three years when stored under recommended conditions. It should be stored in well-closed containers, protected from light, and kept at controlled room temperature (e.g., 20°C to 25°C or 68°F to 77°F). Specific manufacturer recommendations should always be followed.
Are there any known significant impurity concerns associated with the synthesis of dyclonine hydrochloride that tend to be problematic for manufacturers? Common impurity concerns in the synthesis of dyclonine hydrochloride can include related substances from incomplete reactions, degradation products, and residual solvents used during the manufacturing process. Manufacturers must establish stringent in-process controls and final product testing using validated analytical methods, such as HPLC, to identify and quantify these impurities according to pharmacopoeial limits and ICH guidelines.
What impact do raw material price fluctuations have on the overall cost of dyclonine hydrochloride API? Fluctuations in the cost of key starting materials and intermediate chemicals used in the multi-step synthesis of dyclonine hydrochloride can significantly impact its final API price. If the cost of a critical precursor rises, manufacturers typically pass this increase on to their customers to maintain profit margins. Conversely, a decrease in raw material costs can lead to lower API pricing.

Citations

[1] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM website]

[2] U.S. Food and Drug Administration (FDA). (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (n.d.). ICH Harmonised Tripartite Guideline Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH website]

Bulk Pharmaceutical API Sources for dyclonine hydrochloride